HF-158K1 by HighField Biopharmaceuticals for Pancreatic Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.

To fight U.S. tariffs, Canada should suspend U.S. patents on medicines, one expert argues

Now that the Trump administration has imposed 25% tariffs on goods from Canada, the Canadian government is levying tariffs in return. But other measures are

March 4, 2025

Biogen expects to reduce headcount by 1,000 under $700M operational savings plan

Fresh off two FDA green lights — a full approval for Alzheimer’s and an accelerated nod in ALS — Biogen CEO Chris Viehbacher is bringing

July 26, 2023

Plant proteins found to mimic human immune signaling proteins

Researchers have shown that certain plant proteins resemble human signaling proteins of the immune system and can bind to their receptors.

November 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.